DOP063 Serial tuberculin skin test improves the detection of latent tuberculosis infection in inflammatory bowel disease patients

    loading  Checking for direct PDF access through Ovid

Abstract

Background: Despite preventive action, active tuberculosis (TB) still occurs in patients on anti-TNF therapy. Steroids and/or immunosuppressants markedly reduce sensitivity of tuberculin skin test (TST) performed before anti-TNF therapy. The risk of conversion of serial TST in inflammatory bowel disease (IBD) patients whose initial 2-step TST was negative is not well known. This study aimed to determine the likelihood of detecting latent TB infection by the positive conversion of annual TST in IBD patients.

Methods: This prospective multicentre controlled study included consecutive IBD patients on anti-TNF therapy and a control cohort of IBD patients not receiving anti-TNF therapy. All patients with a negative initial 2-step TST had a second test one year later. We evaluated the rate and predictors of TST conversion (including change in number of immunosuppressive drugs [steroids and/or immunosuppressants and/or anti-TNF]). We recorded management of cases of TST conversion and occurrence of active TB during follow-up.

Results: The 412 patients enrolled (mean age 44 years, 54% male) included 192 patients (47%) on anti-TNF and 220 controls (53%). Thirty-five patients (8.5%, 95% confidence interval [CI]: 5.7–11.3) had a positive conversion in the annual TST (median TST induration 13 mm, range 5–20]). Eleven of 192 anti-TNF patients (5.8%, 95% CI 2.2–9.3) vs. 24 of 220 controls (10.9%, 95% CI 6.6–15.2) had TST conversion (p=0.037). In multivariate analysis patients receiving anti-TNF therapy had a lower rate of TST conversion (odds ratio [OR] 0.36, 95% CI 0.15–0.83, p=0.017). Conversely, smokers had a higher rate of TST conversion (OR 3.62, 95% CI 1.66–7.88, p=0.001). The likelihood of conversion according to changes in immunosuppressive therapy from baseline was 16.6%, 7.9%, 7.3%, 4.5% and 0% for patients with 1 drug less, same number of drugs or 1, 2 or 3 drugs more, respectively (p=0.016). All 11 anti-TNF cohort patients with an annual positive TST received treatment for latent TB infection and continued with anti-TNF therapy. Eleven of 24 control patients with TST conversion received preventive therapy. No patient developed active TB after 607 and 676 patient-years of follow-up of anti-TNF exposed and control patients, respectively.

Conclusions: Patients with IBD were at high risk of conversion in the annual TST after an initial negative 2-step TST. Anti-TNF therapy reduced the likelihood of annual TST conversion. Although the exact significance of these positive conversions is not well known, annual TST seems to be advisable as baseline false negative responses to latent TB infection or new TB contacts are possible in IBD patients receiving long-term anti-TNF therapy, especially in countries with a moderate to high prevalence of TB.

Related Topics

    loading  Loading Related Articles